+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Lupin Ltd (LUPIN) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 72 Pages
  • July 2024
  • GlobalData
  • Lupin Ltd
  • ID: 1315549
Lupin Ltd (LUPIN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Lupin Ltd (Lupin) is a global pharmaceutical company primarily engaged in the development and distribution of a diverse range of healthcare products. The company's portfolio includes products, with a focus on generics, branded generics, complex generics, APIs, biosimilars, and specialty medicines. Lupin's products cater to various therapeutic areas such as respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health, serving patients and communities worldwide. The company undertakes extensive research and development activities of pharmaceuticals for the treatment of migraine, gastrointestinal, psoriasis, central nervous system, cardiovascular, diabetes, tuberculosis, inflammation and others. Lupin also develops value-added generic pharmaceuticals based on its platform technologies. The company's products are distributed worldwide, indicating a broad distribution network. Lupin operates across multiple geographic locations, including the US, LATAM, APAC, EMEA, and India, targeting key markets in these regions. Lupin is headquartered in Mumbai, Maharashtra, India.

Lupin Ltd Key Recent Developments

  • Jul 16, 2024: Lupin Receives Tentative Approval from U.S. FDA for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets
  • Jul 12, 2024: Lupin Receives EIR from U.S. FDA for its Dabhasa Facility
  • Jun 22, 2024: Lupin Receives EIR from U.S. FDA for its Somerset Manufacturing Facility
  • Jun 14, 2024: Lupin Announces Closure of US FDA Inspection at its Injectable Facility with Zero 483 Observations

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Lupin Ltd - Key Facts
  • Lupin Ltd - Key Employees
  • Lupin Ltd - Key Employee Biographies
  • Lupin Ltd - Major Products and Services
  • Lupin Ltd - History
  • Lupin Ltd - Company Statement
  • Lupin Ltd - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 - Company Analysis
  • Company Overview
  • Lupin Ltd - Business Description
  • Business Segment: Others
  • Overview
  • Performance
  • Business Segment: Pharmaceuticals
  • Overview
  • Performance
  • Geographical Segment: India
  • Performance
  • Geographical Segment: Others
  • Performance
  • Geographical Segment: USA
  • Performance
  • R&D Overview
  • Lupin Ltd - Corporate Strategy
  • Lupin Ltd - SWOT Analysis
  • SWOT Analysis - Overview
  • Lupin Ltd - Strengths
  • Lupin Ltd - Weaknesses
  • Lupin Ltd - Opportunities
  • Lupin Ltd - Threats
  • Lupin Ltd - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Lupin Ltd, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Jul 16, 2024: Lupin Receives Tentative Approval from U.S. FDA for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets
  • Jul 12, 2024: Lupin Receives EIR from U.S. FDA for its Dabhasa Facility
  • Jun 22, 2024: Lupin Receives EIR from U.S. FDA for its Somerset Manufacturing Facility
  • Jun 14, 2024: Lupin Announces Closure of US FDA Inspection at its Injectable Facility with Zero 483 Observations
  • May 15, 2024: Lupin Achieves Significant Milestone with ISO 14001 and ISO 45001 Certification Across All its Indian Manufacturing Sites, R&D Center and Corporate Office
  • May 06, 2024: Lupin Q4 FY2024 Results
  • May 06, 2024: Lupin : Announces Board changes
  • Apr 23, 2024: Lupin Receives EIR from US FDA for its Aurangabad Manufacturing Facility
  • Apr 23, 2024: Partex Partners with Lupin to Revolutionize Drug Discovery with AI-Driven Asset Search & Evaluation
  • Apr 03, 2024: Lupin Appoints Dr. Ranjana Pathak as Chief Quality Officer
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Lupin Ltd, Key Facts
  • Lupin Ltd, Key Employees
  • Lupin Ltd, Key Employee Biographies
  • Lupin Ltd, Major Products and Services
  • Lupin Ltd, History
  • Lupin Ltd, Other Locations
  • Lupin Ltd, Subsidiaries
  • Lupin Ltd, Joint Venture
  • Lupin Ltd, Key Competitors
  • Lupin Ltd, Ratios based on current share price
  • Lupin Ltd, Annual Ratios
  • Lupin Ltd, Interim Ratios
  • Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Lupin Ltd, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Lupin Ltd, Performance Chart (2020 - 2024)
  • Lupin Ltd, Ratio Charts
  • Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Lupin Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Cipla Ltd
  • Abbott India Ltd
  • Aarti Drugs Ltd
  • Sun Pharmaceutical Industries Ltd
  • Dr. Reddy's Laboratories Ltd
  • Intas Pharmaceuticals Ltd
  • Lincoln Pharmaceuticals Ltd
  • Divi's Laboratories Ltd